康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

ANNOUNCEMENT ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE PROPOSED ISSUE OF A SHARES
INSIDE INFORMATION FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS
Monthly Return of Equity Issuer on Movements in Securities
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT - CENTER FOR DRUG EVALUATION GRANTED PRIORITY REVIEW STATUS TO NEW DRUG APPLICATION FOR QUADRA-VALENT MENINGOCOCCAL CONJUGATE VACCINE
ARTICLES OF ASSOCIATION
POLL RESULTS OF THE 2019 FIRST EXTRAORDINARY GENERAL MEETING, THE 2019 FIRST CLASS MEETING OF H SHAREHOLDERS AND THE 2019 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED ...
List of Directors and their Roles and Functions
Revised Form of Proxy for use at the 2019 First Extraordinary General Meeting to be held on Friday, November 29, 2019
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTS NEW DRUG APPLICATION FOR QUADRA-VALENT MENINGOCOCCAL CONJUGATE VACCINE

1 44 45 46 47 48 52